Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03966612

Study and Monitoring of Multiple Endocrine Neoplasia Type 1

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,600 (estimated)
Sponsor
Centre Hospitalier Universitaire Dijon · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Multiple Endocrine Neoplasia Type I (MEN1) is a rare autosomal dominant disorder, predisposing sufferers to the development of endocrine tumors. The three most commont endocrine disorders of MEN1 are the secretory tumours of the parathyroid, pituitary gland and pancreas, in addition to which other tumours may be observed. The diagnosis of MEN1 is essential for 1) appropriate therapeutic management of proven endocrine disorders, 2) screening for other endocrine and non-endocrine tumours, 3) family screening of affected relatives and 4) monitoring of patients who have been diagnosed. Undiagnosed MEN1 is one of the reasons for therapeutic failure in the management of endocrine damage. Detection is therefore of major importance, and any improvement in early diagnosis can improve management. The natural history of the disease in all its clinical forms remains poorly understood, with published studies of selected or small populations. There are still clinical forms that are difficult to link to the syndrome. These clinical forms need to be specified in order to ensure optimal management. Only a large cohort will lead to the identification of the various forms of this condition and clarify its prognosis.

Conditions

Interventions

TypeNameDescription
OTHERQuestionnairesQuestionnaires about: * Socio-professional situation * Lifestyle * Health * NME 1 * specific breast cancer survey * Imaging

Timeline

Start date
2019-04-05
Primary completion
2028-12-01
Completion
2029-11-01
First posted
2019-05-29
Last updated
2024-07-29

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03966612. Inclusion in this directory is not an endorsement.